Crinetics Pharmaceuticals Inc Stock News

In a report released yesterday, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Crinetics Pharmaceuticals (CRNX – Research

Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 6.) * Forty Seven Inc (NASDAQ: FTSV) * Masimo Corporat

Crinetics Pharmaceuticals Inc:

Crinetics Pharmaceuticals (NASDAQ:CRNX) reports positive interim data from a Phase 2 clinical trial, ACROBAT EDGE, evaluating oral paltusotine (CRN00808) in patients with acromegaly, a rare disorder i

Data from initial patients who have completed the ongoing open label Edge trial show that IGF-1 levels were maintained after 13 weeks of treatment when patients were switched to once daily oral paltus

Data from initial patients who have completed the ongoing open label Edge trial show that IGF-1 levels were maintained after 13 weeks of treatment when...

Crinetics Pharmaceuticals (NASDAQ:CRNX)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued on Friday, TipRanks reports. They currently have a $35.00 price objective

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dynavax (DVAX), Crinetics Pharmaceuticals (CRNX) and

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dynavax (DVAX

Citigroup Inc. grew its holdings in Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) by 90.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchang

Brokerages expect that Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) will report earnings of ($0.63) per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estim

Crinetics Pharmaceuticals (NASDAQ: CRNX) recently received a number of ratings updates from brokerages and research firms: 3/18/2020 – Crinetics Pharmaceuticals had its “overweight” rating reaff

Cantor Fitzgerald restated their overweight rating on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) in a research report released on Wednesday, Zacks.com reports. A number of other equities analys

Barclays PLC boosted its stake in shares of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) by 87.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commiss

Zacks Investment Research upgraded shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) from a hold rating to a buy rating in a report published on Thursday morning, Zacks.com reports. The firm currently